Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Director · CEO & President · 10% owner | June 08, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Med. Dev. Group & CMO | October 01, 2008 | October 02, 2008 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2036-06-08 | IndirectBy Spouse | 8,150 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 8,150 · Balance 8,150 F1: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2: The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Dr. Gregoire's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F2: The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Dr. Gregoire's continued service through the applicable vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date October 01, 2008 · Filed October 02, 2008
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,792 |
Ending reported balance
After 2008-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2008-10-01 · Exercise / conversion · Acquired 4,253 · Balance 141,045 Row 2 · 2008-10-01 · Sale · Disposed 4,253 · Balance 136,792 F1: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $32.65 (range $32.30 to $33.08). F3: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.63 · Expires 2008-12-09 | Direct | 12,761 |
Reported balance
After 2008-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2008-10-01 · Exercise / conversion · Disposed 4,253 · Balance 12,761 F4: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,140 |
Reported balance
Holding disclosure · report date 2008-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,140 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $32.65 (range $32.30 to $33.08).
F3: Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2006 Filed Oct 19, 2006 17:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $36.26 | $54,390.00 |
DisclosureSEC source: 0000875320-06-000086 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,856 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| October 18, 2006 Filed Oct 19, 2006 17:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,500 | $18.47 | $27,705.00 |
DisclosureSEC source: 0000875320-06-000086 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2006 Filed Oct 12, 2006 17:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0000875320-06-000084 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,995 Underlying: Common Stock · 7,500 shares Expires 2007-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 9/26/1997. Read SEC document |
| October 11, 2006 Filed Oct 12, 2006 17:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,500 | $35.35 | $265,125.00 |
DisclosureSEC source: 0000875320-06-000084 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,856 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| October 11, 2006 Filed Oct 12, 2006 17:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $18.47 | $138,525.00 |
DisclosureSEC source: 0000875320-06-000084 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2006 Filed Sep 7, 2006 17:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,500 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0000875320-06-000078 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,495 Underlying: Common Stock · 1,500 shares Expires 2007-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 9/26/1997. Read SEC document |
| September 06, 2006 Filed Sep 7, 2006 17:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $35.59 | $53,385.00 |
DisclosureSEC source: 0000875320-06-000078 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,856 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| September 06, 2006 Filed Sep 7, 2006 17:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,500 | $18.47 | $27,705.00 |
DisclosureSEC source: 0000875320-06-000078 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2006 Filed Aug 31, 2006 18:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0000875320-06-000076 · edgar.xml · derivative · entry 4 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,995 Underlying: Common Stock · 7,500 shares Expires 2007-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 9/26/1997. Read SEC document |
| August 30, 2006 Filed Aug 31, 2006 18:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,500 | $35.00 | $262,500.00 |
DisclosureSEC source: 0000875320-06-000076 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,856 F1 · kind: Transaction made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1. Read SEC document |
| August 30, 2006 Filed Aug 31, 2006 18:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $18.47 | $138,525.00 |
DisclosureSEC source: 0000875320-06-000076 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2006 Filed Jul 24, 2006 17:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 36,250 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0000875320-06-000061 · edgar.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Dev. Group & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,495 Underlying: Common Stock · 36,250 shares Expires 2016-07-19 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/06. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 73,500 | $0.00 Strike: $35.64 | $0.00 |
DisclosureSEC source: 0000875320-06-000012 · edgar.xml · derivative · entry 3 ALAM JOHN J · CIK 0001197014 · EVP, Med. Product Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,245 Underlying: Common Stock · 73,500 shares Expires 2016-02-01 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/02/2006. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,200 | $0.01 | $122.00 |
DisclosureSEC source: 0000875320-06-000012 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · EVP, Med. Product Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,856 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 2/2/2010, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| December 14, 2005 Filed Dec 15, 2005 19:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,750 | $27.59 | $48,282.50 |
DisclosureSEC source: 0000875320-05-000073 · edgar.xml · nonDerivative · entry 3 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,714 Read SEC document |
| December 14, 2005 Filed Dec 15, 2005 19:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 250 | $27.58 | $6,895.00 |
DisclosureSEC source: 0000875320-05-000073 · edgar.xml · nonDerivative · entry 2 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,464 Read SEC document |
| December 14, 2005 Filed Dec 15, 2005 19:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,220 | $27.40 | $88,228.00 |
DisclosureSEC source: 0000875320-05-000073 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,714 Read SEC document |
| July 20, 2005 Filed Jul 22, 2005 19:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-05-000042 · edgar.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,745 Underlying: Common Stock · 18,000 shares Expires 2015-07-19 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/05. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 24,750 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-05-000005 · edgar.xml · derivative · entry 3 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,745 Underlying: Common Stock · 24,750 shares Expires 2015-02-02 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,700 | $0.01 | $57.00 |
DisclosureSEC source: 0000875320-05-000005 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,934 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 2/3/2009, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| October 07, 2004 Filed Oct 12, 2004 18:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-04-000103 · edgar.xml · derivative · entry 1 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,995 Underlying: Common Stock · 18,000 shares Expires 2014-10-06 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
| May 06, 2004 Filed May 10, 2004 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 65,000 | $0.01 | $650.00 |
DisclosureSEC source: 0000875320-04-000045 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,234 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting 50% on May 6, 2009, subject to acceleration upon achievement of a performance-based milestone based on Company profitability, and 50% on May 6, 2007. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 28,350 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-04-000017 · edgar.xml · derivative · entry 3 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,995 Underlying: Common Stock · 28,350 shares Expires 2014-03-16 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 03/17/04. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,780 | $0.01 | $37.80 |
DisclosureSEC source: 0000875320-04-000017 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,234 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 3/17/2008, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 14,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-03-000053 · edgar.xml · derivative · entry 3 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,645 Underlying: Common Stock · 14,400 shares Expires 2013-12-10 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 12/11/2003. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-03-000053 · edgar.xml · nonDerivative · entry 1 ALAM JOHN J · CIK 0001197014 · SVP, Drug Eval. & Appr. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,454 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting in 4 equal annual installments from 12/11/2003. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.